Broadview Ventures

Relief Cardiovascular is a medical technology company focused on developing an innovative smart implant aimed at treating congestive heart failure. The company's implantable device is designed to monitor blood flow and alleviate congestion in the heart, thereby improving health outcomes for patients suffering from this condition. By providing a targeted treatment option, Relief Cardiovascular aims to enhance the quality of life for individuals with heart failure.

Alveron Pharma is a biotechnology company focused on developing treatments for hemorrhagic stroke, a condition with significant unmet medical needs. Their lead drug candidate, OKL-1111, has shown promise in reducing hematoma expansion in preclinical mouse models of intracranial hemorrhage. This drug is designed as an injection solution that is ready to use, aiming to eliminate the need for complex pre-treatment processes. Alveron Pharma's technology centers around cyclodextrins and procoagulant cyclodextrins, which are used to create anticoagulant reversal drugs. These innovations target excessive bleeding in various contexts, including hemophilia, trauma, surgery, and bleeding related to the use of anticoagulants, thereby providing both acute and long-term therapeutic options for thromboembolic disorders.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, specializing in treatments for pulmonary arterial hypertension (PAH). Founded in 2010 by Drs. John Scandurra and Karl Vollmers, the company has developed an innovative implantable cardiovascular device aimed at reducing the workload on the right side of the heart. This device holds the potential to enhance both the survival and quality of life for patients suffering from pulmonary hypertension. Aria CV has secured an exclusive license for certain patents from the University of Minnesota, reflecting its commitment to advancing medical technology in this critical area of healthcare.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions in patients experiencing heart attacks. The company has created a controlled flow infusion system that utilizes a proprietary concept to measure microvascular resistance, allowing interventional cardiologists to assess the severity of microvascular obstruction. By comparing these measurements with post-procedure contrast-enhanced magnetic resonance imaging, CorFlow's technology aims to improve the diagnosis and treatment of microvascular obstruction, potentially reducing both short- and long-term complications for severe heart attack patients. Through its advancements, CorFlow is committed to addressing significant unmet medical needs in cardiology.

XII Medical is a medical device developer focused on addressing obstructive sleep apnea through innovative technology. The company specializes in creating a minimally invasive outpatient solution that utilizes an implantable neurostimulation device. This device functions by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage. By enhancing oropharyngeal airflow, XII Medical aims to provide patients with a proactive approach to managing their sleep apnea, improving their overall quality of life.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

IsomAb is a biotechnology company focused on the evaluation and development of isoform-specific antibodies aimed at treating diseases, particularly peripheral arterial disease. The company's innovative platform targets altered isoforms of pathogenic messenger ribonucleic acid and vascular endothelial growth factor A, which are implicated in various ischemic conditions. By addressing these specific isoforms, IsomAb aims to enhance blood flow and prevent collateral formation in affected patients. This approach provides new therapeutic options for diseases that currently have limited treatment alternatives, potentially improving outcomes for individuals suffering from these conditions.

Cardiosense is a company that focuses on developing a physiological waveform AI platform aimed at creating predictive biomarkers for disease detection and treatment. By mining raw biosignals, Cardiosense provides enhanced visibility into cardiac functions and employs advanced signal processing techniques to identify pre-symptomatic markers of cardiac disease. The company specializes in utilizing non-invasive sensors and proprietary algorithms, which allow healthcare professionals to monitor and analyze cardiac health signals effectively. This innovative approach enables the early detection of diseases, thereby facilitating improved patient care and health tracking.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

XII Medical is a medical device developer focused on addressing obstructive sleep apnea through innovative technology. The company specializes in creating a minimally invasive outpatient solution that utilizes an implantable neurostimulation device. This device functions by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage. By enhancing oropharyngeal airflow, XII Medical aims to provide patients with a proactive approach to managing their sleep apnea, improving their overall quality of life.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Puzzle Medical Devices Inc. is a Montreal-based company founded in 2018 that specializes in developing advanced heart pump devices for the treatment of heart failure. The company's flagship product, the ModulHeart, features a modular design that allows for percutaneous implantation, providing hemodynamic support through multiple pumps anchored in parallel in the descending aorta. This innovative approach aims to reduce cardiac afterload and enhance renal perfusion for patients with advanced heart failure who are not candidates for heart transplants or surgical mechanical circulatory support. The ModulHeart is designed to improve patient mobility, minimize risks of complications such as bleeding and stroke, and enhance overall quality of life by offering sustained symptom relief and reducing re-hospitalizations. Puzzle Medical has made significant progress, having completed its first-in-human study in 2022, which showed improvements in cardiac and kidney function in all participants, and received FDA Breakthrough Device Designation in 2021.

Kantum Pharma, operating as Kantum Bio, is a biotechnology company focused on developing therapeutic and diagnostic solutions for acute kidney injury (AKI). Founded in 2016 and based in Concord, New Hampshire, the company is advancing its lead therapeutic candidate, KB-1801, aimed at the prophylaxis and treatment of AKI, particularly in patients undergoing cardiovascular interventions. In addition to its therapeutic efforts, Kantum Bio is creating a novel urinary diphosphate glucose (UDP-G) diagnostic test designed to facilitate the early identification of patients at risk for AKI. This dual approach not only seeks to prevent significant mortality associated with AKI but also aims to enhance treatment selection in clinical settings. Kantum's innovative strategies position it to address critical needs in the management of AKI, particularly in intensive care environments.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Basking Biosciences is a startup focused on developing innovative therapies for ischemic stroke. The company is creating a reversible thrombolytic therapy aimed at restoring blood flow to the brain during such events, which can help prevent hemorrhage and minimize long-term damage. Their platform features a paired therapy that combines an active agent targeting a critical component of clot stability with a designed reversal agent. This reversal agent can be administered if bleeding occurs, neutralizing the active compound and restoring normal clotting ability. This dual approach enables healthcare professionals to provide effective treatment for acute ischemic stroke patients.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

Alleviant Medical, Inc. is a medical device company headquartered in Austin, Texas, that specializes in developing innovative therapies for congestive heart failure. Founded in 2017, the company has created a proprietary transcatheter device that addresses the symptoms of heart failure by relieving pressure buildup in the left atrium of the heart. This minimally-invasive technology aims to improve the quality of life for patients and significantly reduce hospital admissions related to heart failure exacerbations, ultimately benefiting millions of Americans affected by this condition. Alleviant Medical is committed to transforming the treatment landscape for congestive heart failure through its advanced medical devices.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, specializing in innovative solutions for cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, which allows for temporary pacing through a parasternal approach. This system advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium, effectively restoring cardiac rhythm without the need for traditional pacing leads or hardware that typically attach directly to the heart. By facilitating quick deployment of temporary or emergency pacing therapy, AtaCor Medical addresses critical needs in cardiac care.

Puzzle Medical Devices Inc. is a Montreal-based company founded in 2018 that specializes in developing advanced heart pump devices for the treatment of heart failure. The company's flagship product, the ModulHeart, features a modular design that allows for percutaneous implantation, providing hemodynamic support through multiple pumps anchored in parallel in the descending aorta. This innovative approach aims to reduce cardiac afterload and enhance renal perfusion for patients with advanced heart failure who are not candidates for heart transplants or surgical mechanical circulatory support. The ModulHeart is designed to improve patient mobility, minimize risks of complications such as bleeding and stroke, and enhance overall quality of life by offering sustained symptom relief and reducing re-hospitalizations. Puzzle Medical has made significant progress, having completed its first-in-human study in 2022, which showed improvements in cardiac and kidney function in all participants, and received FDA Breakthrough Device Designation in 2021.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Kantum Pharma, operating as Kantum Bio, is a biotechnology company focused on developing therapeutic and diagnostic solutions for acute kidney injury (AKI). Founded in 2016 and based in Concord, New Hampshire, the company is advancing its lead therapeutic candidate, KB-1801, aimed at the prophylaxis and treatment of AKI, particularly in patients undergoing cardiovascular interventions. In addition to its therapeutic efforts, Kantum Bio is creating a novel urinary diphosphate glucose (UDP-G) diagnostic test designed to facilitate the early identification of patients at risk for AKI. This dual approach not only seeks to prevent significant mortality associated with AKI but also aims to enhance treatment selection in clinical settings. Kantum's innovative strategies position it to address critical needs in the management of AKI, particularly in intensive care environments.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Renovacor, Inc., established in 2013 and headquartered in Philadelphia, Pennsylvania, is a biopharmaceutical company dedicated to developing transformative gene therapies for cardiovascular diseases. Currently in the preclinical stage, Renovacor's primary focus is on creating a recombinant adeno-associated virus (AAV)-based gene therapy targeting patients with dilated cardiomyopathy (DCM) caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This condition affects approximately 35,000 individuals in the United States and Europe, qualifying it as an orphan disease. Renovacor aims to improve patient outcomes by potentially preventing disease progression through a BAG3 gene replacement therapy, given the current five-year survival rate of only 50% for DCM patients despite standard care.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. The company utilizes its proprietary XTreo technology platform, which allows for the precise and sustained delivery of medications directly to affected tissues through a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy for chronic rhinosinusitis. The active ingredient in these products is mometasone furoate, known for its established efficacy and safety profile in various FDA-approved medications. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics aims to improve treatment outcomes for patients suffering from ENT diseases.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, specializing in innovative solutions for cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, which allows for temporary pacing through a parasternal approach. This system advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium, effectively restoring cardiac rhythm without the need for traditional pacing leads or hardware that typically attach directly to the heart. By facilitating quick deployment of temporary or emergency pacing therapy, AtaCor Medical addresses critical needs in cardiac care.

Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, specializing in innovative solutions for patients with congestive heart failure. Founded in 2011, the company has developed the V-LAP, the first in-heart microcomputer designed to enhance treatment for heart failure patients by facilitating daily monitoring of left atrial pressure (LAP). This miniature wireless implant is a groundbreaking device that operates without batteries and can transmit data from deep within the body, offering a reliable means of detecting potential deterioration in heart failure. The V-LAP has been recognized as an effective predictor of heart failure worsening, thereby improving patients' quality of life and life expectancy. Vectorious is currently conducting clinical studies in various European countries, including Italy, Germany, and the UK, to obtain regulatory approval, with plans to initiate a clinical study in the United States.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, founded in 2012. The company specializes in manufacturing medical devices utilizing advanced surgical anastomotic technology aimed at treating obesity and type 2 diabetes. G.I. Windows is focused on developing innovative solutions that enable less invasive surgical procedures, thereby creating a new category in healthcare. Its technology is designed to enhance the efficiency of diagnostic and interventional procedures, ultimately improving patient outcomes while reducing overall healthcare costs.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

Adient Medical Inc. is a company focused on the development and delivery of absorbable medical devices, specifically designed to prevent pulmonary embolism. Founded in 2012 and headquartered in Pearland, Texas, Adient Medical's flagship product is an absorbable vascular filter that provides an effective solution for patients at risk of this condition. The company operates on the principle that implants should remain safe and effective throughout their useful lifespan and then dissolve without the need for surgical removal, thereby minimizing the risk of complications and reducing healthcare costs associated with removal procedures. Through its innovative approach, Adient Medical aims to enhance patient safety and improve outcomes in vascular care.

Mellitus, LLC specializes in the development of in vitro diagnostic tests aimed at measuring Glycated CD59 (GCD59), a novel biomarker with significant potential in the clinical management of diabetes. The company focuses particularly on a diagnostic test for the screening of gestational diabetes mellitus, which aids healthcare professionals in identifying potential risks within minutes. Additionally, Mellitus's technology serves a dual purpose, facilitating the stratification of complications risk and functioning as a clinical trial test for pharmaceutical development. Founded in 2011, Mellitus is headquartered in Boston, Massachusetts, and is dedicated to advancing diabetes detection and monitoring through innovative diagnostic solutions.

CellAegis Devices Inc. is a Toronto-based company that specializes in developing, manufacturing, and commercializing medical devices. Its flagship product, the autoRIC Device, delivers remote ischemic conditioning (RIC) in a non-invasive manner to protect the heart during heart attacks and other cardiovascular procedures. This automated device is designed for use in various settings, including hospitals, ambulances, and at home. Additionally, the company provides the CRICtrac mobile app, which enables clinicians to offer patients self-administered chronic RIC therapy at home. CellAegis Devices serves a broad market across Canada and Europe, focusing on enhancing patient care through innovative medical technology.

Nido is a medical device manufacturer specializing in innovative solutions for cardiac procedures. The company is developing SEPIA, an advanced Epicardial Ablation Solution aimed at treating cardiac arrhythmias, particularly ventricular tachycardia. This novel platform allows for video-endoscopic trans-cardiac surgical repairs within the beating heart, which enhances the precision and effectiveness of interventions. Nido's device is designed to be inserted through small incisions in the chest and heart wall, facilitating minimally invasive surgeries while eliminating the need for cardiopulmonary bypass. This technology, developed from research at Boston Children's Hospital, underscores Nido's commitment to improving patient outcomes in cardiac care.

Aeromics, LLC is a preclinical biotechnology company based in Cleveland, Ohio, focused on developing innovative therapies for treating cerebral edema, particularly in stroke patients. Founded in 2006 and operating as a subsidiary of Case Western Reserve University, Aeromics is advancing AER-271, a drug candidate designed to block aquaporin-4 (AQP4), a key molecular water channel at the blood-brain barrier. This therapeutic approach aims to mitigate brain swelling associated with ischemic stroke, cardiac arrest, and other conditions that lead to edema. By targeting AQP4, Aeromics seeks to offer a novel treatment option that enhances recovery prospects for patients suffering from acute central nervous system edema, thereby addressing a critical gap in therapeutic agents that effectively manage water homeostasis in the brain.

Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

Gila Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for obesity and metabolic diseases. Founded in 2014 and based in Minneapolis, Minnesota, the company is working on GT-002, a PYY3-36 agonist designed to promote weight loss by decreasing caloric intake and enhancing feelings of fullness. Gila Therapeutics employs innovative routes of administration to deliver its therapies, aiming to provide non-invasive solutions for weight management. Through its research and development efforts, the company seeks to offer effective treatments that address the growing challenges associated with obesity.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, specializing in treatments for pulmonary arterial hypertension (PAH). Founded in 2010 by Drs. John Scandurra and Karl Vollmers, the company has developed an innovative implantable cardiovascular device aimed at reducing the workload on the right side of the heart. This device holds the potential to enhance both the survival and quality of life for patients suffering from pulmonary hypertension. Aria CV has secured an exclusive license for certain patents from the University of Minnesota, reflecting its commitment to advancing medical technology in this critical area of healthcare.

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Epirium Bio, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for cardiovascular diseases, metabolic syndrome, and disorders characterized by mitochondrial dysfunction. Founded in 2008, the company leverages unique insights into mitochondrial biology and tissue regeneration to create a small molecule platform aimed at improving muscle strength and facilitating tissue regeneration. Epirium Bio's innovative approach addresses significant clinical needs in treating neuromuscular, neurodegenerative, and mitochondrial disorders, enabling healthcare providers to better support patients suffering from conditions such as muscular dystrophy.

Pulmokine is a privately held biopharmaceutical company dedicated to developing innovative therapies for challenging lung conditions, particularly pulmonary arterial hypertension and related disorders such as pulmonary arterial fibrosis, sarcoidosis, and lung cancer. The company leverages its expertise in pulmonary disease and kinase inhibitor technology to create targeted treatments that aim to improve patient outcomes for those suffering from these serious conditions. Through its focused research and development efforts, Pulmokine endeavors to address unmet medical needs in the field of pulmonary medicine.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, focused on developing medical treatments for atrial fibrillation (AF), the most prevalent type of cardiac arrhythmia. Founded in 2011, Acesion Pharma specializes in creating SK channel inhibitors that aim to provide safe and tolerable chronic treatments for AF. These drugs work by inhibiting specific ion channels in heart cells, which are crucial for generating the electrical signals that regulate the heart's rhythm. The company's goal is to offer effective solutions for preventing the recurrence of atrial fibrillation and maintaining normal heart rhythm, thereby improving the quality of life for patients affected by this condition.

Ischemia Care, LLC is a molecular diagnostic company based in Oxford, Ohio, that specializes in blood tests aimed at diagnosing the causes of ischemic strokes and transient ischemic attacks. Founded in 2002 and known previously as Gerard Ventures, LLC, the company offers various diagnostic tools, including the ISCDx test for stroke diagnosis based on gene expression analysis, which is critical for stratifying patients and guiding appropriate treatment. Additionally, it provides the ER Stroke Triage Test for quick confirmation of stroke in emergency settings and conducts laboratory testing under CLIA regulations. By utilizing blood testing as a clinical workflow tool, Ischemia Care enhances patient outcomes and aims to reduce hospital costs, empowering clinicians with vital information to prevent stroke recurrence and ensure timely interventions.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

InfoBionic, Inc., incorporated in 2011 and based in Lowell, Massachusetts, specializes in remote patient monitoring technologies, particularly focusing on cardiac arrhythmia detection. The company has developed the MoMe System, a cloud-based platform that allows for continuous monitoring of electrocardiogram, respiration, and motion data. This wireless system streamlines the remote patient monitoring process, enhancing both clinical efficiency and patient care by enabling healthcare providers to access patient data anytime and anywhere. InfoBionic's innovative approach aims to transform the economics of cardiac diagnostic services, benefiting both physicians and patients through improved detection and treatment of cardiac complications.

ZZ Biotech, LLC is a clinical-stage biotechnology company based in Houston, Texas, founded in 2006. The company specializes in developing innovative biological treatments aimed at addressing conditions affecting the aging and damaged brain, particularly ischemic stroke and other neurodegenerative disorders. ZZ Biotech's lead product, 3K3A-APC, is a genetically engineered variant of the naturally occurring activated Protein C (APC). This variant is designed to maintain the beneficial cytoprotective and anti-inflammatory properties of APC while significantly reducing its anticoagulant activity, which is associated with bleeding risks. Preclinical studies suggest that 3K3A-APC offers superior efficacy compared to wild-type APC. The company is currently conducting a multicenter Phase 2 clinical trial to evaluate the safety, tolerability, and effectiveness of 3K3A-APC in patients experiencing moderate to severe ischemic stroke, particularly in conjunction with treatments like tissue Plasminogen Activator (tPA) and mechanical thrombectomy. This research is supported by grants from the National Institutes of Health.

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company based in New York, focused on developing small molecule drugs for acute central nervous system disorders. Founded in 2004, the company targets conditions such as stroke, traumatic brain injury, spinal cord injury, organ ischemia, and complications arising from CNS surgery. Its lead product, RP-1127, is an intravenous formulation of glyburide, which inhibits NCCa-ATP channels and works by antagonizing the type-1 sulfonylurea receptor. Remedy Pharmaceuticals aims to enhance treatment options for healthcare professionals dealing with patients suffering from various nervous system disorders.

Apama Medical, Inc. is a medical device company that specializes in catheter ablation technology for the treatment of atrial fibrillation (AF). Founded in 2009 and based in Campbell, California, the company offers a radiofrequency balloon catheter system designed to enhance the effectiveness of ablation procedures. This innovative system integrates multi-electrode technology, allowing for the delivery of energy in a manner that combines the advantages of both point-by-point and balloon-based ablation techniques. The system features built-in digital cameras, LED lights, and sensing electrodes, which facilitate real-time visualization and assessment of catheter electrode contact during procedures. Apama Medical operates in the rapidly growing electrophysiology market, aiming to improve the detection and treatment of heart rhythm disorders. Since October 2017, the company has been a subsidiary of Boston Scientific Corporation.

BioKier, Inc. is an early-stage pharmaceutical company based in Chapel Hill, North Carolina, focused on developing innovative treatments for diabetes and related disorders. Incorporated in 2008, the company specializes in proprietary oral medications aimed at managing glucose levels, particularly for individuals with type 2 diabetes, metabolic syndrome, and obesity. BioKier's lead product features L-glutamine, a natural compound found in various foods, which is designed to replicate the mechanisms of metabolic bypass surgery. Through its research and development efforts, BioKier aims to provide effective solutions that can significantly improve the management of diabetes for patients.

Zumbro Discovery, Inc. is focused on developing a novel natriuretic peptide, MANP, aimed at addressing resistant hypertension, a condition that poses significant health risks including heart failure, myocardial infarction, stroke, and kidney disease. Discovered at the Mayo Clinic, MANP is set to enter first-in-human studies, highlighting its potential as a critical therapeutic option for patients with this unmet medical need. By targeting cardiovascular and metabolic diseases, Zumbro Discovery seeks to enhance treatment outcomes and facilitate quicker interventions in clinical settings.

DecImmune Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative peptides and antibodies to address acute tissue-damaging inflammation associated with conditions such as myocardial infarction, burns, and vascular injury. The company aims to create therapeutics that treat second-degree burns and prevent reperfusion injury in transplant patients. It has made significant advancements in monoclonal antibodies targeting innate pathways to mitigate tissue damage and preserve organ function, particularly in the context of vascular inflammatory diseases. Founded in 2001 and originally named Natural Antibodies, Inc., DecImmune Therapeutics has since established itself as a key player in the field of inflammation and autoimmunity.

Laurantis Pharma Oy is a specialty pharmaceutical development company with a broad, clinical-stage portfolio in three therapeutic areas: dermatology, ophthalmology, and oncology. Using two proprietary technologies, Laurantis is developing first-in-class products for commercially and medically significant niche indications in these areas. Laurantis was formed in December 2010 through a merger of the Finnish drug development companies Oy Lx Therapies Ltd and BioCis Pharma Oy.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

InfoBionic, Inc., incorporated in 2011 and based in Lowell, Massachusetts, specializes in remote patient monitoring technologies, particularly focusing on cardiac arrhythmia detection. The company has developed the MoMe System, a cloud-based platform that allows for continuous monitoring of electrocardiogram, respiration, and motion data. This wireless system streamlines the remote patient monitoring process, enhancing both clinical efficiency and patient care by enabling healthcare providers to access patient data anytime and anywhere. InfoBionic's innovative approach aims to transform the economics of cardiac diagnostic services, benefiting both physicians and patients through improved detection and treatment of cardiac complications.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Vascular Graft Solutions Ltd. is an Israeli company founded in 2009, dedicated to developing innovative medical devices aimed at improving the outcomes of bypass surgeries and enhancing patients' quality of life. The company's flagship product, VEST, is specifically designed for use in Coronary Artery Bypass Grafting (CABG) procedures. It addresses the critical issue of vascular graft failure by mitigating disease progression in venous bypass grafts, thereby improving their long-term performance. In addition to VEST, Vascular Graft Solutions specializes in external stents and scaffolds for cardiac and vascular surgery, focusing on solutions that tackle the challenges associated with vein graft diseases, surgical revascularization, vascular reconstruction, and arteriovenous fistula procedures.

Cardialen, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in developing innovative therapies for heart arrhythmias, particularly atrial fibrillation. Founded in 2008, the company focuses on creating implantable devices that provide low-energy, pain-free cardioversion therapies to restore normal heart rhythm. These devices utilize a proprietary technology that delivers a sequential series of low-voltage pulses to effectively address atrial fibrillation and other related conditions, such as rapid ventricular tachycardia and ventricular fibrillation, while minimizing patient discomfort and protecting heart tissue from damage. By targeting significant unmet medical needs, Cardialen aims to improve the quality of life for individuals suffering from these heart conditions.

Apama Medical, Inc. is a medical device company that specializes in catheter ablation technology for the treatment of atrial fibrillation (AF). Founded in 2009 and based in Campbell, California, the company offers a radiofrequency balloon catheter system designed to enhance the effectiveness of ablation procedures. This innovative system integrates multi-electrode technology, allowing for the delivery of energy in a manner that combines the advantages of both point-by-point and balloon-based ablation techniques. The system features built-in digital cameras, LED lights, and sensing electrodes, which facilitate real-time visualization and assessment of catheter electrode contact during procedures. Apama Medical operates in the rapidly growing electrophysiology market, aiming to improve the detection and treatment of heart rhythm disorders. Since October 2017, the company has been a subsidiary of Boston Scientific Corporation.

Provasculon is a biotechnology company founded to leverage a significant discovery made by Dr. Richard Lee and Dr. Vincent Segers at Brigham and Women's Hospital. The company focuses on the development of novel therapeutic proteins, particularly those related to the growth factor Stromal Cell-Derived Factor-1 (SDF-1). Provasculon's lead product is designed to aid in the healing of organs affected by ischemia, specifically targeting heart tissue that has suffered severe ischemic damage. This therapeutic approach aims to restore normal cardiac function, representing a potential advancement in the treatment of ischemic conditions.

Aggamin Pharmaceuticals, LLC is a biotechnology company established in 2010 and located in New York. The company focuses on developing and commercializing innovative therapies for vascular diseases, with a primary emphasis on preeclampsia, a serious condition affecting about 5% of pregnancies and imposing a significant financial burden on the U.S. healthcare system. Aggamin's lead product is an extracorporeal device designed to reduce harmful circulating proteins associated with preeclampsia, aiming to improve both maternal and fetal health. By restoring the angiogenic balance disrupted in this condition, the company's objective is to provide a safe, first-in-class treatment that alleviates maternal symptoms, extends pregnancy duration, and enhances outcomes for both mothers and newborns.

Coridea is an idea generator, technology incubator, and consulting firm specializing in the development of medical devices aimed at improving the lives of patients with cardiac, pulmonary, renal, and neuro conditions. Established in 2003, Coridea has successfully launched six startup companies, including Ardian and CHF Solutions, and has achieved significant milestones such as the high-profile acquisition of Ardian by Medtronic. The firm holds 65 U.S. patents, which have been licensed to various companies in the medical field, and has raised over $150 million in venture capital financing. Coridea is recognized for its innovative contributions to medical technology, notably the award-winning Symplicity® Catheter System™, which offers novel solutions to complex clinical problems. Through its focus on applying existing technologies to new medical challenges, Coridea aims to redefine the medical landscape and enhance patient care.

NuPulseCV, Inc. is a medical device company focused on developing innovative treatments for patients with heart failure. The company specializes in the iVAS intravascular ventricular assist system, an investigational device designed to provide a minimally invasive alternative to traditional medical therapies for advanced heart failure patients. This device aims to alleviate symptoms and improve the quality of life for individuals who are not responding to standard treatments, allowing for potential discharge from the hospital and a return to daily activities. Founded in 2010 and based in Raleigh, North Carolina, NuPulseCV boasts a team with extensive expertise in clinical, engineering, and life sciences. The company collaborates strategically with a leading firm in the heart failure sector to enhance the development and evaluation of its technologies through clinical trials.

Cardialen, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in developing innovative therapies for heart arrhythmias, particularly atrial fibrillation. Founded in 2008, the company focuses on creating implantable devices that provide low-energy, pain-free cardioversion therapies to restore normal heart rhythm. These devices utilize a proprietary technology that delivers a sequential series of low-voltage pulses to effectively address atrial fibrillation and other related conditions, such as rapid ventricular tachycardia and ventricular fibrillation, while minimizing patient discomfort and protecting heart tissue from damage. By targeting significant unmet medical needs, Cardialen aims to improve the quality of life for individuals suffering from these heart conditions.

Capricor Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of biological therapies for various diseases, particularly focusing on Duchenne muscular dystrophy (DMD) and other rare disorders. The company is advancing its lead product candidate, CAP-1002, an allogeneic cell therapy currently undergoing phase II clinical trials for late-stage DMD. Additionally, CAP-1002 has been explored in trials for other cardiac conditions, including heart failure and post-myocardial infarction complications. Capricor is also developing CAP-2003, which is in pre-clinical stages for treating inflammatory conditions. Founded in 2005, the company is headquartered in Beverly Hills, California.

CellAegis Devices Inc. is a Toronto-based company that specializes in developing, manufacturing, and commercializing medical devices. Its flagship product, the autoRIC Device, delivers remote ischemic conditioning (RIC) in a non-invasive manner to protect the heart during heart attacks and other cardiovascular procedures. This automated device is designed for use in various settings, including hospitals, ambulances, and at home. Additionally, the company provides the CRICtrac mobile app, which enables clinicians to offer patients self-administered chronic RIC therapy at home. CellAegis Devices serves a broad market across Canada and Europe, focusing on enhancing patient care through innovative medical technology.

Intravascular Imaging is a company focused on advancing cardiovascular imaging technologies to enhance the early detection of coronary artery disease and improve post-interventional therapeutic viability. Established through a collaboration between Massachusetts General Hospital/Harvard Medical School and the Technical University of Munich, the company develops innovative techniques for detecting and stratifying atherosclerotic plaques in human arteries. Its offerings include prototype devices, software, and systems aimed at reducing hospital readmissions following percutaneous coronary interventions. By providing a comprehensive catheter-based approach, Intravascular Imaging enables healthcare professionals to identify high-risk plaques, ultimately improving patient outcomes in cardiovascular care.

Allosteros Therapeutics Inc. engages in discovery and development of breakthrough small molecule drugs that target allosteric sites on key proteins in disease pathways. Allosteros Therapeutics Inc. was incorporated in 2009 and is based in Palo Alto, California.

VentriNova is a regenerative medicine company dedicated to reversing cardiac damage by activating intrinsic repair pathways to generate new heart muscle cells. The company specializes in developing innovative gene therapies aimed at treating heart tissue degeneration. Its lead product is a gene therapy that introduces a crucial mitotic regulator into diseased heart tissue, promoting the proliferation of cardiac muscle cells. By focusing on these regenerative approaches, VentriNova aims to provide effective clinical treatments for patients suffering from heart failure.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

CardiAQ Valve Technologies is a privately held company dedicated to advancing heart valve replacement procedures. Its primary focus is on developing innovative techniques for transcatheter mitral valve implantation (TMVI), aiming to enable physicians to implant mitral valves within a beating heart without the need for open-heart surgery.